Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Under Armour Inc Class A (UA) Price & Performance

Heron Therapeutics IncTrade
Under Armour Inc Class ATrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Under Armour Inc Class A — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Under Armour Inc Class A trades at $7.18 (market cap $3.07B). The key difference: Under Armour Inc Class A is far larger — about 33.6× Heron Therapeutics Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXUA
Market Cap
$91.46M$3.07B
Sector
HealthConsumer Cyclical
52-Week High
$1.96$7.88
52-Week Low
$0.39$3.96
Enterprise Value
$189.36M$4.70B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

Under Armour Inc Class A

Under Armour (UA) trades at $7.13, down 2.06% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $201.27 million for 2025, with revenue of $5.16 billion, and faces declining revenue projections for 2026. Recent news includes a Dodge collaboration and an upcoming Q1 2027 earnings call on August 7, 2026.

The outlook remains challenged by negative profitability and cash flow, though analyst consensus leans slightly bullish with 40.3% buy ratings. Key risks include sustained revenue declines and high debt, while potential upside hinges on successful execution of premium product focus and inventory management strategies.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Under Armour Inc Class A

Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.

Read more on UA